The miR-193a-3p-regulated ING5 gene activates the DNA damage response pathway and inhibits multi-chemoresistance in bladder cancer

Oncotarget

Volumn 6, Issue 12, 2015, Pages 10195-10206

  Li, Yang ^a   Deng, Hui ^b   Lv, Lei ^b   Zhang, Cheng ^c   Qian, Liting ^b   Xiao, Jun ^b   Zhao, Weidong ^b   Liu, Qi ^d   Zhang, Daming ^e   Wang, Yingwei ^c   Yan, Jun ^c   Zhang, Hongyu ^f   He, Yinghua ^f   Zhu, Jingde ^b,f  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Anhui Cancer Hospital   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d HARBIN INSTITUTE OF TECHNOLOGY   (China)

^e THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^f SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bladder cancer; Chemoresistance; ING5; miR 193a 3p; Protein acetylation

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; MICRORNA; MICRORNA 193A 3P; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ING5 PROTEIN, HUMAN; MIRN193 MICRORNA, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLADDER CANCER; CELL DEATH; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DAMAGE; GENE; GENE ACTIVITY; GENE EXPRESSION; HIC2 GENE; ING5 GENE; MOUSE; NONHUMAN; PLAU GENE; PROTEIN EXPRESSION; PROTEIN OVEREXPRESSION; RNA SEQUENCE; SRSF2 GENE; TUMOR XENOGRAFT; UPREGULATION; ACETYLATION; ANIMAL; BIOSYNTHESIS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; NUDE MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; MICRORNAS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929593738     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3555     Document Type: Article

References (43)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64(1):9-29.
2. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. Journal of Clinical Oncology. 2005; 23(21):4602-4608.
3. Cimino GD, Pan C-x and Henderson PT. Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. Bioanalysis. 2013; 5(3):369-391.
4. Chang JS, Lara PN and Pan C-X. Progress in personalizing chemotherapy for bladder cancer. Advances in urology. 2012; 2012.
5. Gordon RR and Nelson PS. Cellular senescence and cancer chemotherapy resistance. Drug Resistance Updates. 2012; 15(1):123-131.
6. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A and Tarpey P. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine. 2012; 366(10):883-892.
7. JG Marin J, Briz O, J Monte M, G Blazquez A and IR Macias R. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs. Current cancer drug targets. 2012; 12(4):402-438.
8. Li F and Sethi G. Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochimica Et Biophysica Acta (BBA)-Reviews on Cancer. 2010; 1805(2):167-180.
9. Capaccione KM and Pine SR. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis. 2013; 34(7):1420-1430.
10. Abbotts R, Thompson N and Madhusudan S. DNA repair in cancer: emerging targets for personalized therapy. Cancer management and research. 2014; 6:77.
11. Landriscina M, Maddalena F, Laudiero G and Esposito F. Adaptation to oxidative stress, chemoresistance, and cell survival. Antioxidants & redox signaling. 2009; 11(11):2701-2716.
12. Ahmad S. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chemistry & biodiversity. 2010; 7(3):543-566.
13. Sau A, Pellizzari Tregno F, Valentino F, Federici G and Caccuri AM. Glutathione transferases and development of new principles to overcome drug resistance. Archives of biochemistry and biophysics. 2010; 500(2):116-122.
14. Leslie EM, Deeley RG and Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicology and applied pharmacology. 2005; 204(3):216-237.
15. Borst P, Evers R, Kool M and Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. Journal of the National Cancer Institute. 2000; 92(16):1295-1302.
16. Tan B, Piwnica-Worms D and Ratner L. Multidrug resistance transporters and modulation. Current opinion in oncology. 2000; 12(5):450-458.
17. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G and Keppler D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer research. 1996; 56(5):988-994.
18. Fu L, Liu N, Han Y, Xie C, Li Q and Wang E. ADAM10 regulates proliferation, invasion, and chemoresistance of bladder cancer cells. Tumor Biology. 2014:1-6.
19. Lin J, Zhang Q, Lu Y, Xue W, Xu Y, Zhu Y and Hu X. Downregulation of HIPK2 Increases Resistance of Bladder Cancer Cell to Cisplatin by Regulating Wip1. PloS one. 2014; 9(5):e98418.
20. Hayden A, Douglas J, Sommerlad M, Andrews L, Gould K, Hussain S, Thomas GJ, Packham G and Crabb SJ. (2014). The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. Urologic Oncology: Seminars and Original Investigations: Elsevier).
21. L Lv HD, Y Li, C Zhang, X Liu, Q Liu, D Zhang, L Wang, Y Pu, H Zhang, Y He, Y Wang, Y Yu, T Yu and J Zhu. The DNA methylation-regulated miR-193a-3p dictates the multi-chemoresistance of bladder cancer via repression of SRSF2/PLAU/HIC2 expression. Cell Death & Disease. 2014; 5:e1402.
22. Lei Lv, Yang Li, Hui Deng, Cheng Zhang, Youguang Pu, Liting, Qian, Jun Xiao, Weidong Zhao, Qi Liu, Daming Zhang, Yingwei Wang, Hongyu Zhang, Yinghua He, Jingde Zhu. " MiR-193a-3p promotes the multi-chemoresistance of bladder cancer by targeting the HOXC9 gene." Cancer Lett. 2015 Feb 1;357(1):105-13
23. Hui Deng, Lei Lv, Yang Li, Cheng Zhang, Fang Meng, Youguang Pu, Jun Xiao, Liting Qian, Weidong Zhao, Qi Liu, Daming Zhang, Yingwei Wang, Hongyu Zhang, Yinghua He, Jingde Zhu. "The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer." Biochim Biophys Acta. 2014 Dec 24;1852(3):520-528
24. Hui Deng, Lei Lv, Yang Li, Cheng Zhang, Fang Meng, Youguang Pu, Jun Xiao, Liting Qian, Weidong Zhao, Qi Liu, Daming Zhang, Yingwei Wang, Hongyu Zhang, Yinghua He, Jingde Zhu. "miR-193a-3p regulates the multidrug resistance of bladder cancer by targeting the LOXL4 gene and the Oxidative Stress pathway." Molecular Cancer 2014 Oct 14;13:234
25. Deng H, Lv L, Li Y, Zhang C, Meng F, Pu Y, Xiao J, Qian L, Zhao W, Liu Q, Zhang D, Wang Y, Zhang H, He Y and Zhu J. The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer. Biochimica et biophysica acta. 2014; 1852(3):520-528.
26. Lv L, Li Y, Deng H, Zhang C, Pu Y, Qian L, Xiao J, Zhao W, Liu Q, Zhang D, Wang Y, Zhang H, He Y and Zhu J. MiR-193a-3p promotes the multi-chemoresistance of bladder cancer by targeting the HOXC9 gene. Cancer Lett. 2015; 357(1):105-113.
27. Liu N, Wang J, Wang J, Wang R, Liu Z, Yu Y and Lu H. ING5 Is a Tip60 cofactor that acetylates p53 in response to DNA damage. Cancer research. 2013; 73(12):3749-3760.
28. Doyon Y, Cayrou C, Ullah M, Landry A-J, Côté V, Selleck W, Lane WS, Tan S, Yang X-J and Côté J. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Molecular cell. 2006; 21(1):51-64.
29. Iizuka M, Sarmento OF, Sekiya T, Scrable H, Allis CD and Smith MM. Hbo1 Links p53-dependent stress signaling to DNA replication licensing. Molecular and cellular biology. 2008; 28(1):140-153.
30. Coles AH and Jones SN. The ING gene family in the regulation of cell growth and tumorigenesis. Journal of cellular physiology. 2009; 218(1):45-57.
31. Jafarnejad SM and Li G. Regulation of p53 by ING family members in suppression of tumor initiation and progression. Cancer and Metastasis Reviews. 2012; 31(1-2):55-73.
32. Guérillon C, Larrieu D and Pedeux R. ING1 and ING2:multifaceted tumor suppressor genes. Cellular and Molecular Life Sciences. 2013; 70(20):3753-3772.
33. Shiseki M, Nagashima M, Pedeux RM, Kitahama-Shiseki M, Miura K, Okamura S, Onogi H, Higashimoto Y, Appella E and Yokota J. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer research. 2003; 63(10):2373-2378.
34. Kim J-W, Jang S-M, Kim C-H, An J-H, Kang E-J and Choi K-H. New molecular bridge between RelA/p65 and NF-κB target genes via histone acetyltransferase TIP60 cofactor. Journal of Biological Chemistry. 2012; 287(10):7780-7791.
35. Dey A, Tergaonkar V and Lane DP. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways. Nature Reviews Drug Discovery. 2008; 7(12):1031-1040.
36. Wadgaonkar R, Phelps KM, Haque Z, Williams AJ, Silverman ES and Collins T. CREB-binding protein is a nuclear integrator of nuclear factor-κB and p53 signaling. Journal of Biological Chemistry. 1999; 274(4):1879-1882.
37. Patel JH, Du Y, Ard PG, Phillips C, Carella B, Chen C-J, Rakowski C, Chatterjee C, Lieberman PM and Lane WS. The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Molecular and cellular biology. 2004; 24(24):10826-10834.
38. Heyne K, Winter C, Gerten F, Schmidt C and Roemer K. A novel mechanism of crosstalk between the p53 and NFκB pathways: MDM2 binds and inhibits p65RelA. Cell Cycle. 2013; 12(15):2479-2492.
39. Hoffman B and Liebermann D. Apoptotic signaling by c-MYC. Oncogene. 2008; 27(50):6462-6472.
40. Ho JS, Ma W, Mao DY and Benchimol S. p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Molecular and cellular biology. 2005; 25(17):7423-7431.
41. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nature Reviews Cancer. 2006; 6(9):663-673.
42. Champagne KS and Kutateladze TG. Structural insight into histone recognition by the ING PHD fingers. Current drug targets. 2009; 10(5):432.
43. Ullah M, Pelletier N, Xiao L, Zhao SP, Wang K, Degerny C, Tahmasebi S, Cayrou C, Doyon Y and Goh S-L. Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes. Molecular and cellular biology. 2008; 28(22):6828-6843.